Protease inhibitor 141W94/VX-478: Phase II trial

The antiviral efficacy, tolerability and pharmacokinetics of 900 or 1200 mg of the agent (twice daily) will be tested against the combination of the 900 mg dose with AZT and 3TC. Patients not responding adequately to monotherapy can switch to the combination. The trial also will assess penetration of the protease blocker into the cerebrospinal fluid in a subset of volunteers.

The 24-week trial will be funded by the NIH, VRTX, and the company's collaborators, Glaxo Wellcome plc and Kissei Pharmaceutical Co. Ltd. ...